8-K current report · filed Oct 5, 2026

Vaxcyte, Inc. (PCVX) 8-K Current Report: October 5, 2026

Item 7.01Item 8.01Item EX-99.1Item EX-99.2PCVX overview

Short answer

Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Positive topline OPUS-1 Phase 3 data for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate.

Vaxcyte, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Positive topline OPUS-1 Phase 3 data for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate
  • Adult trial assessed safety, tolerability and immunogenicity, supporting potential advancement toward regulatory submission
  • VAX-31 targets invasive pneumococcal disease and pneumococcal pneumonia, expanding potential commercial market opportunity
  • Detailed results are in Exhibit 99.1, the October 5, 2026 press release

Item 8.01 · Other Events

  • Vaxcyte made an investor slide presentation available on October 5, 2026
  • Exhibit 99.2 contains the substantive disclosure and may provide updates on pipeline programs, clinical data, or corporate strategy

Item EX-99.1 · Exhibit EX-99.1

  • OPUS-1 Phase 3 success: VAX-31 met all primary endpoints across studied age groups, materially de-risking its adult regulatory path
  • Broader coverage with preserved immunity: 28 shared serotypes met noninferiority, while three unique serotypes and 20B achieved superiority
  • PCV21 comparison remains a review focus: 17 of 19 shared serotypes met the >0.667 threshold, while serotypes 3 and 12F exceeded historical >0.5
  • Safety comparable to PCV20 and PCV21, with no vaccine-related serious adverse events or discontinuations
  • OPUS-2 and OPUS-3 results expected first half 2027, supporting planned BLA submission first half 2028

Item EX-99.2 · Exhibit EX-99.2

  • OPUS-1 Phase 3 success: all 32 immunogenicity comparisons met noninferiority, supporting VAX-31’s planned BLA submission
  • Broad coverage advantage: designed for 95% of adult IPD and 88% of pneumococcal pneumonia, 13-36% and 19-31% above standard vaccines
  • Differentiated efficacy: superiority across 4 unique serotypes plus cross-reactive 20B versus PCV20 and/or PCV21
  • Safety comparable to competitors: 1.2% serious adverse events in adults ≥50, with zero vaccine-related serious events or discontinuations
  • Commercial and regulatory catalysts: OPUS-2 and OPUS-3 topline results anticipated in 1H 2027, alongside manufacturing and launch preparations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vaxcyte, Inc. 8-K filings

Get the next PCVX 8-K as it lands

Follow PCVX for push alerts, or ask the research agent what this filing means.